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Osteoporosis is a serious problem worldwide; it is characterized by bone fractures in 
response to relatively mild trauma. Osteoclasts originate from the fusion of macrophages 
and they play a central role in bone development and remodeling via the resorption of bone. 
Therefore, osteoclasts are important mediators of bone loss that leads, for example, to 
osteoporosis. Interleukin (IL)-1 receptor (IL-1R)–associated kinase M (IRAK-M) is only 
expressed in cells of the myeloid lineage and it inhibits signaling downstream of IL-1R and 
Toll-like receptors (TLRs). However, it lacks a functional catalytic site and, thus, cannot 
function as a kinase. IRAK-M associates with, and prevents the dissociation of, IRAK–IRAK-4–
TNF receptor–associated factor 6 from the TLR signaling complex, with resultant disruption 
of downstream signaling. Thus, IRAK-M acts as a dominant negative IRAK. We show here 
that mice that lack IRAK-M develop severe osteoporosis, which is associated with the 
accelerated differentiation of osteoclasts, an increase in the half-life of osteoclasts, and 
their activation. Ligation of IL-1R or TLRs results in hyperactivation of NF-
 
 
 
B and mitogen-
activated protein kinase signaling pathways, which are essential for osteoclast differentiation. 
Thus, IRAK-M is a key regulator of the bone loss that is due to osteoclastic resorption of bone.
 
Multinucleated osteoclasts originate from the
fusion of mononuclear phagocytes and play a
major role in the resorption of bone. Because
osteoclasts are essential for the development
and remodeling of bone, increases in their
number and/or activity lead to diseases that are
associated with generalized bone loss (e.g., os-
teoporosis) and others with localized bone loss
(e.g., rheumatoid arthritis, periodontal disease).
The cytokines macrophage colony–stimu-
lating factor (M-CSF) and receptor activator of
NF-
 
 
 
B (RANKL) are necessary and sufficient
for the induction of the differentiation of osteo-
clasts from mononuclear phagocytes (1–6), but
agonists of IL-1R/Toll-like receptor (TLR) also
play a critical role in the differentiation and
 
 
 
acti-
vation of osteoclasts. IL-1 is a potent stimulator
of the differentiation, activation and survival of
osteoclasts that have been implicated in post-
menopausal osteoporosis (7), whereas LPS, a
ligand that binds to TLR4, is responsible for the
inflammation-mediated loss of bone (8). Bone
loss that is associated with estrogen deficiency in
rodents can be prevented by
 
 
 
administration of
an antagonist of IL-1R (9, 10); however, bone
loss that is associated with infection remains dif-
ficult to control, even in model systems.
IL-1R–associated kinase (IRAK) plays a
central role in the signaling pathways that are
initiated by members of the IL-1R/TLR
family (11). Members of this family have a
conserved “TLR- and IL-1R-related” intra-
cytoplasmic domain.
 
 
 
Thus, activation of the
different
 
 
 
members of this family induces simi-
lar signaling cascades that culminate in the ac-
tivation of the I
 
 
 
B kinase complex and mito-
gen-activated protein kinases (MAPKs). This
activation leads to the activation of NF-
 
 
 
B,
c-Jun NH
 
2
 
-terminal kinase (JNK), p38, and
extracellular signal-regulated kinase (ERK)1/2,
as well as AP-1–dependent transcriptional re-
sponses (12, 13).
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IRAKs are multidomain proteins with a similar central
kinase domain and a death domain that interacts with mye-
loid differentiation factor 88. All IRAKs have a functional
ATP-binding site, but IRAK-2 and IRAK-M lack a func-
tional catalytic site because the critical aspartate residue is re-
placed by an asparagine and a serine residue, respectively.
Hence, IRAK-2 and IRAK-M are inactive as kinases. In ad-
dition, IRAK-M is expressed predominantly in peripheral
blood leukocytes and in macrophages (14). IRAK-M is ex-
pressed in monocytic cell lines and its expression is induced
strongly upon the maturation of macrophages (14). We re-
ported previously that IRAK-M acts as a negative regulator
of IL-1R/TLR signaling by preventing the dissociation of
IRAKs from myeloid differentiation factor 88 and maintain-
ing the integrity of the complex between IRAK–TNF re-
ceptor–associated factor (TRAF)6 and TLR (15). By trap-
ping both types of IRAK in the receptor complex, IRAK-M
prevents the downstream activation of NF-
 
 
 
B and MAPK
signaling pathways. Thus, IRAK-M seems to act as a domi-
nant negative regulator downstream of IL-1R/TLR in mac-
rophages (15). Therefore, we postulated that if the expression
of IRAK-M is conserved in macrophages after the fusion that
results in multinucleation, it should be a negative regulator of
the differentiation and activation of osteoclasts, and thus, it
should protect bone mass. To test our hypothesis, we exam-
ined mice with a homozygous deletion of the 
 
irak-M
 
 gene.
We found that
 
 
 
in normal mice, IRAK-M is expressed
strongly in osteoclasts and that its absence is associated with
accelerated osteoclastogenesis; an increase in the half-life of
osteoclasts; and the hyperactivation of the NF-
 
 
 
B and
MAKP signaling pathways, via ligation to IL-1R/TLR, with
severe resultant osteoporosis. IRAK-M seems to be a key sig-
naling molecule in the prevention of bone loss.
 
RESULTS
IL-1 receptor–associated kinase M–deficient mice 
develop osteoporosis
 
IRAK-M
 
 
 
/
 
 
 
 mice are viable and fertile but seem to develop
an accentuated spinal curvature or kyphosis at 4 mo of age
(data not shown). At this age, IRAK-M
 
 
 
/
 
 
 
 mice are smaller
than wild-type mice (Fig. 1 A). To assess bone density in
IRAK-M
 
 
 
/
 
 
 
 mice, we subjected femurs from 4-mo-old
IRAK-M
 
 
 
/
 
 
 
 and IRAK-M
 
 
 
/
 
 
 
 mice to peripheral quantita-
tive computed tomography analysis at the midshaft level. The
cortical content was lower in IRAK-M
 
 
 
/
 
 
 
 mice than in age-
matched IRAK-M
 
 
 
/
 
 
 
 mice (Table I). This difference was as-
sociated with a decrease in the diameter of femurs, in males
and females, and a decrease in cortical thickness in males. At
the level of the epiphysis, the trabecular content and density
 
Figure 1. IRAK-M–deficient mice are smaller than wild-type mice 
and have reduced total bone mineral density.
 
 (A) Male and female 
IRAK-M
 
 
 
/
 
 
 
 mice are smaller than IRAK-M
 
 
 
/
 
 
 
 mice; 
 
n
 
 
 
 
 
 10. (B) microCT 
analysis of distal femurs from 4-mo-old male IRAK-M
 
 
 
/
 
 
 
 and IRAK-M
 
 
 
/
 
 
 
 
mice. Note the paucity of the trabeculae inside the bone in IRAK-M
 
 
 
/
 
 
 
 
mice. The wider diameter of the bone sections measures 
 
 
 
3 mm. Bar, 1 
mm. (C) Toluidine blue staining of sections from epiphyseal bones from 
4-mo-old male IRAK-M
 
 
 
/
 
 
 
 and IRAK-M
 
 
 
/
 
 
 
 mice. Bar, 1 mm. (D) TRAP 
staining of sections from epiphyseal bones from 4-mo-old male IRAK-M
 
 
 
/
 
 
 
 
and IRAK-M
 
 
 
/
 
 
 
 mice. Bar, 200 
 
 
 
m. 
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were reduced in male and female IRAK-M
 
 
 
/
 
 
 
 mice, as com-
pared with sex- and age-matched IRAK-M
 
 
 
/
 
 
 
 
 
mice. This
decrease in trabecular bone density was associated with a 60%
reduction in trabecular bone volume, as determined by mi-
croCT analysis (Fig. 1 B). Together, our data indicated that
the deletion of the 
 
irak-M
 
 gene in mice leads to osteoporosis.
 
Increased numbers of osteoclasts in IL-1 receptor–
associated kinase M–deficient mice
 
To examine the mechanism by which bone density was re-
duced in IRAK-M–deficient mice, we analyzed tibias from
4-mo-old IRAK-M
 
 
 
/
 
 
 
 and IRAK-M
 
 
 
/
 
 
 
 mice by histo-
morphometry. Our analysis confirmed the reduction in tra-
becular bone volume in male and female IRAK-M
 
 
 
/
 
 
 
 mice
(Table II and Fig. 1 C). At the cellular level, we found an in-
crease in the number of osteoclasts per unit area of bone sur-
face (Fig. 1 D). This was associated, in males, with an in-
crease in the number of osteoblasts, which indicated an
elevated
 
 
 
rate of bone turnover. Thus, the absence of IRAK-M
led to a reduction in body size and bone mass that was asso-
ciated with an increase in the number of osteoclasts.
 
Accelerated osteoclastogenesis and an increase in the 
half-life of osteoclasts in IL-1 receptor–associated 
kinase M–deficient mice
 
To determine whether the increase in the number of osteo-
clasts in IRAK-M
 
 
 
/
 
 
 
 mice might be the result of an increase
in the rate of differentiation of their precursors, we treated
bone marrow macrophages from male IRAK-M
 
 
 
/
 
 
 
 and
IRAK-M
 
 
 
/
 
 
 
 mice for increasing times with M-CSF to gen-
erate osteoclast precursors (16). To our surprise, IRAK-M
 
 
 
/
 
 
 
cells proliferated at a lower rate (Fig. 2 A) but fused more
rapidly than IRAK-M
 
 
 
/
 
 
 
 cells (Fig. 2 B).
Next, to examine whether the differentiation of osteo-
clasts was affected by the absence of IRAK-M, we treated
bone marrow macrophages with increasing concentrations of
M-CSF in the presence of 300 ng/ml RANKL in order to
generate tartrate-resistant acid phosphatase-positive (TRAP
 
 
 
)
multinucleated macrophages with an osteoclast phenotype
(16). IRAK-M
 
 
 
/
 
 
 
 macrophages required as little as 15 ng/ml
M-CSF to reach a maximally multinucleate state, whereas
IRAK-M
 
 
 
/
 
 
 
 cells required 60 ng/ml to reach a maximal
state that was less extensive (Fig. 2, C and
 
 
 
D). However,
higher concentrations of M-CSF tended to have a more lim-
ited effect on multinucleation in IRAK-M
 
 
 
/
 
 
 
 macrophages,
which suggested an increased sensitivity of IRAK-M
 
 
 
/
 
 
 
 cells
to M-CSF. When we treated macrophages with 30 ng/ml
M-CSF in the presence of increasing concentrations of
RANKL, IRAK-M
 
 
 
/
 
 
 
 macrophages matured into
 
 
 
osteo-
 
Table I.
 
Peripheral quantitative computed tomography analysis of femurs from 4-mo-old IRAK-M
 
   
 
 and IRAK-M
 
    
 
male and female mice
 
Femoral shaft Distal femur
Cortical
content
Cortical
density
Cortical
thickness
Periosteal
circumference
Endosteal
circumference
Trabecular
content
Trabecular
density
 
mg/mm mg/cm
 
3
 
mm mm mm mg/mm mg/cm
 
3
 
Male
 
   
 
mean 1.985 1,235.6 0.375 5.462 3.107 0.72 291.65
SD 0.182 21.691 0.024 0.289 0.32 0.041 26.428
Male
 
   
 
mean 1.325 1,173.375 0.337 4.409 2.292 0.295 141.925
SD 0.061 13.579 0.015 0.075 0.124 0.093 46.187
 
 
 
 
 
 
 
/
 
   
 
0.7 0.9 0.9 0.8 0.7 0.4 0.5
p-value
 
 
 
0.01
 
 
 
0.01
 
 
 
0.05
 
 
 
0.01
 
 
 
0.01
 
 
 
0.001
 
 
 
0.01
Female
 
   
 
mean 1.51 1,179.08 0.347 4.801 2.625 0.338 177.04
SD 0.067 30.548 0.021 0.318 0.42 0.025 19.802
Female
 
   
 
mean 1.293 1,169.067 0.327 4.423 2.369 0.107 62.167
SD 0.035 18.003 0.01 0.077 0.135 0.078 47.218
 
 
 
 
 
 
 
/
 
   
 
0.9 1 0.9 0.9 0.9 0.3 0.4
p-value
 
 
 
0.01 NS NS
 
 
 
0.05 NS
 
 
 
0.01
 
 
 
0.05
 
Table II.
 
Histomorphometric analysis of proximal tibiae from 4-mo-old 
IRAK-M    and IRAK-M    male and female mice
BV/TV BFR/BV N.Oc/B.Pm N.Ob./B.Pm OV/BV
mean SD mean SD mean SD mean SD mean SD
% %/d no./mm no./mm %
Male    12.35 2.59 2.01 0.40 2.65 0.49 28.87 6.86 5.14 1.53
Male    6.72 0.16 4.38 1.46 10.50 1.33 40.34 5.60 6.40 0.71
p-value  0.01  0.05  0.001  0.05 NS
   /    0.5 2.2 4.0 1.4 1.2
Female    5.94 1.43 4.88 1.67 2.13 0.63 30.51 4.54 4.25 1.78
Female    3.85 0.75 4.78 0.75 6.77 0.90 37.2910.30 4.58 1.48
p-value  0.05 NS  0.001 NS NS
   /    0.6 0.9 3.2 1.2 1.1IRAK-M SUPRESSES OSTEOCLASTS | Li et al. 1172
Figure 2. Absence of IRAK-M alters osteoclastogenesis in response to 
M-CSF and RANKL. (A) Bone marrow cells from IRAK-M /  and IRAK-M /  
male mice were cultured in the presence of M-CSF (5 ng/ml) for 12–18 h. 
Nonadherent cells were cultured further for the indicated times in 96-well 
dishes and their numbers determined in terms of OD450nm (n   5; see 
Materials and methods for details). Standard deviations are too small to 
show. P   0.001 for IRAK-M /  versus IRAK-M /  macrophages treated 
for 3, 4, and 5 d; P   0.01 for IRAK-M /  versus IRAK-M /  macrophages 
treated for 6 d. (B) Cells from (A) were stained for TRAP. Bar, 100  m. 
(C) Nonadherent cells, prepared as in (A), were treated further with 30 ng/ml 
M-CSF for 2 d, replated in 96-well dishes (2   105 cells/ml), and treated 
with 300 ng/ml RANKL plus with increasing concentrations of M-CSF for 
3 d. The surface area occupied by TRAP  multinucleated osteoclasts was 
recorded (n   4). Standard deviations are too small to show. P   0.001 JEM VOL. 201, April 4, 2005 1173
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clasts at lower concentrations of RANKL than did IRAK-
M /  macrophages (Fig. 2, E and F). However, this differ-
ence between IRAK-M /  and IRAK-M /  macrophages
remained relatively constant with increasing concentrations
of RANKL, except at the highest dose when multinucleation
of macrophages had reached its maximum. Thus, the absence of
IRAK-M tended to favor the multinucleation of macro-
phages, a phenomenon that might explain, in part, the ele-
vated numbers of osteoclasts in IRAK-M /  mice.
To determine whether the half-life of osteoclasts also was
altered in IRAK-M–deficient mice, we cultured osteoclast
precursors in the presence of 30 ng/ml M-CSF plus 300 ng/
ml RANKL for 2, 3, or 4 d, and then we stained the cells for
TRAP. The IRAK-M /  macrophages differentiated into
multinucleated osteoclasts until day 4, by which time the
IRAK-M /  osteoclasts had undergone apoptosis (Fig. 2 G).
Together, these data indicate that the absence of IRAK-M is
associated with an elevated rate of osteoclastogenesis in re-
sponse to M-CSF alone and to M-CSF plus RANKL and to
extension of the half-life of osteoclasts, which would explain
the increased number of osteoclasts in IRAK-M /  mice.
Because M-CSF stimulates the production of cytokines by
macrophages, which affects osteoclastogenesis (17), we pos-
tulated that the absence of IRAK-M might affect the re-
sponse of macrophages to the M-CSF–induced production
of IL-1.
To examine our hypothesis, we determined the relative
amount of IL-1 that accumulated over the course of 12 and
24 h in the conditioned medium from IRAK-M /  and
IRAK-M /  bone marrow macrophages, with and without
stimulation by M-CSF alone and by M-CSF plus RANKL.
Our results confirmed that M-CSF stimulated the release of
IL-1  and IL-1  by macrophages (Table III). RANKL did
not alter that M-CSF–induced production of IL-1. Our
analysis also revealed that the concentrations of IL-1  and
IL-1  were higher in supernatants from macrophages that
were deficient in IRAK-M than in those from wild-type
cells; this supports the hypothesis that IRAK-M intercepts
IL-1R signaling and prevents further production of IL-1.
The lower abundance of IL-1 at 24 h might reflect the par-
tial degradation of IL-1 or its binding to IL-1R.
Next, we asked whether the expression of IRAK-M is
preserved upon multinucleation of macrophages. We treated
IRAK-M /  osteoclasts with 20 ng/ml IL-1  or with 100
 g/ml LPS for increasing times. To our surprise, we found
that unlike macrophages, multinucleated osteoclasts ex-
pressed high levels of IRAK-M, independent of TLR/ IL-
1R ligation (Fig. 3 A). Therefore, we asked whether
RANKL itself could stimulate the expression of IRAK-M.
RANKL induced the expression of IRAK-M in macro-
phages in a time-dependent manner (Fig. 3 B); this observation
explained the high basal level of IRAK-M in osteoclasts.
Hyperactivation of NF- B and mitogen-activated protein 
kinase signaling pathways in response to IL-1R/TLR ligation 
in IL-1 receptor–associated kinase M–deficient osteoclasts
We examined whether the absence of IRAK-M could lead
to hyperactivation of the NF- B and MAPK signaling path-
ways (15). Because IL-1R/TLR ligation affects the differen-
tiation and activation of osteoclasts, we stimulated osteoclasts
from IRAK-M /  and IRAK-M /  mice for increasing
times with IL-1  or IL-1 , both of which are potent ago-
nists of osteoclastic bone resorption. We subjected cell ly-
sates to Western blotting analysis with antibodies that are di-
rected against I B, and the MAPK signaling molecules, p38,
ERK1/2, and JNK, and their phosphorylated, thus  acti-
vated, form. Although p38 is not activated constitutively
in macrophages (15), p38 was activated constitutively in
IRAK-M /  and IRAK-M /  osteoclasts (Fig. 3 C). Both
IL-1  and IL-1  induced the hyperphosphorylation of
for IRAK-M /  versus IRAK-M /  macrophages treated with 7.5, 15, 30, 
and 60 ng/ml M-CSF. (D) Photographs of cells in (C). Bar, 100  m. (E) Non-
adherent cells, prepared as in (A), were treated further with 30 ng/ml 
M-CSF for 2 d, replated in 96-well dishes (2   105 cells/ml), and stimu-
lated with 30 ng/ml M-CSF plus with increasing concentrations of RANKL 
for 3 d. The surface area occupied by TRAP  multinucleated cells was re-
corded (n   4). Standard deviations are too small to show. P   0.001 for 
IRAK-M /  versus IRAK-M /  macrophages at each RANKL concentration. 
(F) Cells from (E) were stained for TRAP. Bar,100  m. (G) Osteoclasts were 
generated as in (E) but were treated with 300 ng/ml RANKL and 30 ng/ml 
M-CSF for the indicated times. Bar, 100  m. Each experiment was repeated 
at least three times with similar results.
Table III. Deletion of the Irak-M gene in mice leads to increased production of IL-1  and IL-1  by bone marrow macrophages that 
are stimulated with M-CSF
12 h 24 h
IRAK-M    IRAK-M       /    IRAK-M    IRAK-M       /   
IL-1  M-CSF 1.09a 1.26a 1.15 0.53a 1.09a 2.06
M-CSF   RANKL 1.27a 1.26a 1.00 0.59a 1.06a 1.80
IL-1  M-CSF 1.59a 2.08a 1.31 0.52a 0.91a 1.75
M-CSF   RANKL 1.52a 1.90a 1.25 0.51a 1.02a 2.00
Each experiment was repeated three times with similar results.
aValues represent the ratios of 12-h or 24-h stimulation with M-CSF or M-CSF plus RANKL over controls (n   2).IRAK-M SUPRESSES OSTEOCLASTS | Li et al. 1174
ERK1/2 and JNK in a time-dependent manner in IRAK-
M /  osteoclasts. By contrast, only IL-1  induced the time-
dependent hyperphosphorylation of I- B in osteoclasts that
lacked IRAK-M.
We next asked whether activation of osteoclasts by LPS,
a ligand for TLR4, and a potent agonist of osteoclastic bone
resorption in vivo, also might be affected by the absence of
IRAK-M. We found that p38 was hyperphosphorylated
constitutively in IRAK-M /  and IRAK-M /  osteoclasts,
independently of TLR4 ligation (Fig. 3 D). As did IL-1, LPS
induced the hyperphosphorylation of ERK1/2 and I B in
IRAK-M /  cells. However, in contrast to the results that
were observed with IL-1, hyperphosphorylation of I B in
IRAK-M /  osteoclasts occurred only 1 or 2 h after stimu-
lation with LPS. LPS failed to activate JNK in IRAK-M / 
and wild-type osteoclasts.
Together, our results show that in macrophages and os-
teoclasts, the absence of IRAK-M leads to hyperactivation of
the NF- B and MAPK signaling pathways in response to IL-
1R/TLR ligation.
Figure 3. Osteoclasts express IRAK-M, and demonstrate hyperacti-
vation of signaling molecules downstream of IL-1R/TLR when IRAK-M 
is absent. (A) Bone marrow macrophages from wild-type mice were cul-
tured in the presence of M-CSF (5 ng/ml) for 12–18 h. Nonadherent cells 
were cultured further for 2 d in 24-well dishes (macrophages) and treated 
for the indicated times with 20 ng/ml IL-1  or 1 mg/ml LPS (macrophages), 
or cultured for an additional 3 d in the presence of 30 ng/ml M-CSF and 
300 ng/ml RANKL (osteoclasts, OC) before activation with IL-1  or LPS. 
Cells were lysed in Laemmli sample buffer supplemented with inhibitors of 
proteases and phosphatases and subjected to Western blotting analysis 
with anti–IRAK-M and anti-GADPH antibodies. (B) Bone marrow macrophages 
from wild-type mice were treated with 300 ng/ml RANKL for the indicated 
times, bone marrow macrophages from IRAK-M-deficient mice were 
treated similarly for 24 h and used as a negative control. Cells were ana-
lyzed as in (B). (C) IRAK-M /  and IRAK-M /  osteoclasts were starved for 
2 h, and then stimulated with 20 ng/ml IL-1 , IL-1 , or 1 mg/ml LPS for 
the indicated times. (D) IRAK-M /  and IRAK-M /  osteoclasts were stimu-
lated with 1 mg/ml LPS for the indicated times. The right lane shows a pos-
itive control for the phosphorylation of JNK. Each experiment was repeated 
three times with similar results. P-p38, phosphorylated p38.JEM VOL. 201, April 4, 2005 1175
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DISCUSSION
IRAK-M is the first signaling molecule that lacks intrinsic
enzymatic activity to be shown to regulate the differentia-
tion, activation, and life span of osteoclasts. During signal
transduction, phosphorylation of signaling molecules repre-
sents the sum, at any given time, of opposing effects of the
kinases and phosphatases that determine the response. By
virtue of its sequence homology to IRAKs, IRAK-M binds
the IRAK/IRAK-4 complex, thereby acting as a dominant
negative IRAK that intercepts signals downstream of IL-
1R/TLR and whose effect is independent of phosphoryla-
tion. The induced expression of IRAK-M is sufficient to
interfere  with IL-1R/TLR signaling. In this report, we
showed that the level of expression of IRAK-M in osteo-
clasts is high as compared with that in macrophages and
that the absence of IRAK-M leads to severe osteoporosis
which is associated with increased numbers of osteoclasts.
These effects seem to be due, in part, to the M-CSF–
induced production of IL-1, which accelerates the rate of
differentiation, extends the half-life, and stimulates the ac-
tivity of osteoclasts (7). Therefore, we propose the follow-
ing model for IRAK-M signaling during osteoclastogenesis
(Fig. 4).
As shown schematically in Fig. 4, M-CSF that is ex-
pressed by bone marrow stromal cells and osteoblasts in-
duces the clonal expansion of macrophages and the release
by them of IL-1, with resultant activation of IL-1R/TLR.
Activation of IL-1R leads to an elevated rate of differentia-
tion, an extended half-life, and the activation of osteoclasts.
RANKL, expressed by bone marrow cells and osteoblasts,
binds receptor activator of NF- B (RANK) and activates
NF- B via TRAF6, which promotes the expression of
IRAK-M. Upon religation of IL-1R, IRAK-M prevents
the dissociation of the IRAK/IRAK-4–TRAF6 complex
and, hence, the downstream activation of NF- B. Overall,
IRAK-M ensures the ability of osteoclasts to tolerate the
effects of IL-1. M-CSF, RANK, TRAF6, and NF- B
are required for osteoclastogenesis (1, 5, 18–20). Hence,
IRAK-M–mediated deactivation of IL-1R allows the tran-
sient activation and survival of osteoclasts. The absence of
IRAK-M leads to constitutive activation of IL-1R/TLR,
constitutive production of IL-1, and the prolonged survival
and activation of osteoclasts. Moreover, IRAK-M also me-
diates tolerance to LPS. Thus, IRAK-M, whose expression
is restricted to myeloid cells and is induced strongly by
RANKL, seems to be a novel and critical down-regulator
of the differentiation and activation of osteoclasts. Because
the expression of IRAK-M is induced by RANKL, which
is required for the maturation, fusion, and differentiation of
macrophages into osteoclasts, expression of IRAK-M pro-
vides a powerful negative feedback mechanism.
Fusion of mononuclear phagocytes is the first step in os-
teoclastogenesis. This explains why mononucleate macro-
phages cannot resorb bone efficiently and leads to osteopetrosis.
Hence, inhibition of the production of IL-1 is an essential
step in the prevention of osteoclastic bone resorption.
Together, increased osteoclastogenesis and the extended
survival of osteoclasts explain the elevated number of osteo-
clasts in IRAK-M /  mice, and, hence, their low bone
mass. It is unclear whether the osteoclasts are individually
more active and resorb bone more efficiently. Although we
have recorded the numbers and the sizes of the “pits” that
are formed in dentin slices by osteoclasts as a function of
time, we have not been able to detect differences between
pits of IRAK-M /  and IRAK-M /  osteoclasts (unpub-
lished data). However, because numbers and half-life of
osteoclasts are increased in IRAK-M /  mice, further in-
creases in their activity would aggravate osteoporosis even
further.
It also is unclear whether the osteoporotic phenotype of
mice that lack IRAK-M is mediated solely by osteoclasts.
Macrophages are present in all tissues and might well con-
tribute, via the cytokines and growth factors that they pro-
duce (e.g., IL-1), to the differentiation and activation of
osteoclasts that leads to osteoporosis. Osteoclasts and macro-
phages share a common precursor and numerous functions.
Thus, there might be cross talk between them.
In terms of phenotype, male mice were affected more se-
verely than female mice by the absence of IRAK-M. Possi-
ble associations between sex hormones and the expression of
IRAK-M remain to be investigated. To avoid confounding
Figure 4. Hypothetical scheme for the role of IRAK-M in the dif-
ferentiation and activation of osteoclasts. Ligation of c-Fms (1) stimu-
lates the production of IL-1, which activates IL-1R. Ligation of RANK (2) 
leads to TRAF6-mediated activation of NF- B (3), and induction of expression 
of IRAK-M, (4) IL-1 activates IL-1R (5), which stimulates osteoclastogenesis 
and the osteoclastic resorption of bone, and extends the half-life of osteo-
clasts. When IRAK-M is present, it prevents IL-1R/TLR-mediated down-
stream signaling and the activation of NF- B. Thus, IRAK-M mediates a 
negative feedback mechanism that interrupts signaling downstream of IL-1R. 
In the absence of IRAK-M, the IL-1 cycle continues without interruption, 
leading to increased osteoclastogenesis, with the hyperactivation and 
prolonged half-life of osteoclasts.IRAK-M SUPRESSES OSTEOCLASTS | Li et al. 1176
effects that were due to gender, we performed our studies
using cells that originated exclusively from same-sex mice,
namely male mice.
Osteoclasts, which originate from the fusion of mono-
nuclear phagocytes, as do the giant cells that are found at
sites of chronic inflammatory reactions and granulomas, not
only express IRAK-M, but express it at higher levels than
mononuclear cells. This supports the possibility that multi-
nucleation might represent a primitive defense mechanism
that evolved to protect organisms against invasive patho-
gens. That same developmental process has endowed mac-
rophages with the ability to resorb bone by differentiating
into osteoclasts. Moreover, macrophage fusion seems to in-
volve the macrophage fusion receptor/signal regulatory
protein  -CD47 (21, 22) axis, and macrophage fusion re-
ceptor shares a common origin with antigen receptors.
Thus, macrophage fusion might have evolved before jawed
vertebrates (23).
IRAK-M is a noncatalytic signaling molecule whose ex-
pression is induced by RANKL. Its potency seems to de-
pend upon its level of expression. Thus, if we could develop
methods for regulating the expression of IRAK-M, we
might be able to control bone mass and move toward pre-
vention of osteoporosis.
MATERIALS AND METHODS
Animals. IRAK-M /  mice were produced by homologous recombina-
tion as described previously (17). Mice were screened by PCR using the
IRAK-M /  forward primer (exon 4–5) 5 -gccagaagaatacatcagacaggg-3  and
reverse primer 5 -tgtttcgggtcatccagcac-3 ; and the IRAK-M /  forward
primer 5 -cgttccataacacacctctctgc-3  and reverse primer 5 -ttctatcgccttcttgac-
gagttc-3 . Animals were housed and bred at the Yale Animal Care facility,
under sterile conditions reserved for immuno-deficient mice, which include
autoclaved caging and food, as well as changing of cages in a clean-air cabi-
net/change station using sterile techniques. Mice whose bones were sub-
jected to histomorphometric analysis received two i.p. injections of calcein (3
 g/g body weight; Merck) on days 1 and 6 before being killed. All experi-
ments were approved by the Yale Animal Care and Use Committee.
Computed tomography on a microscale. The proximal tibiae from
4-mo-old male IRAK-M /  and IRAK-M /  mice were scanned with a
MicroCT 40 scanner (Scanco) with a 2,048   2,048 matrix and isotropic
resolution of 5  m3; three-dimensional trabecular measurements in the sec-
ondary spongiosa were made directly.
Bone densitometry. Bone density was determined as described previ-
ously (24) by peripheral quantitative computed tomography with a Stratec
scanner model XCT 960M (Norland Medical Systems). Routine calibration
was performed daily with a defined standard that contained hydroxyapatite
crystals embedded in lucite, provided by Norland Medical Systems. We
scanned 1-mm–thick slices located at a distance of 3 mm, proximally, from
the distal end of distal femoral metaphyses. The voxel size was set at 0.15
mm. Scans were analyzed with a software program that was supplied by the
manufacturer (XMICE, version 5.1). Bone density and geometric parame-
ters were estimated by Loop analysis. The low- and high-density threshold
settings were 1,300 and 2,000, respectively. Separation of soft tissue from
the outer edge of bone was achieved using contour mode 1. Cortical (high
bone density) and trabecular (low bone density) bone were separated to ob-
tain trabecular data using peel mode 3. Cortical and trabecular bone were
separated to obtain cortical data using cortical mode 1.
Histomorphometry. Tibiae from IRAK-M /  and IRAK-M /  mice
were dehydrated in a graded ethanol series and embedded without decalcifi-
cation in methylmethacrylate, as we described previously (25). Longitudinal
sections were cut with an Autocut microtome with a tungsten carbide blade
(Jung). 4- m-thick sections were stained with toluidine blue (pH 3.7) and
subjected to static histomorphometric analysis, whereas 8- m–thick sec-
tions were mounted (unstained) for dynamic histomorphometric analysis,
which was performed at a constant distance from the growth plate (includ-
ing trabecular bone), with an image analysis system (Osteomeasure; Osteo-
metrics). The measured parameters included the bone volume relative to
the total volume (BV/TV); the rate of bone formation (BFR/BV), which
takes into account the mineral apposition rate; the number of osteoclasts per
active resorption perimeter (N.Oc/B.Pm); the number of osteoblasts per
active formation perimeter (N.Ob/B.Pm); and the osteoid volume relative
to bone volume (OV/BV).
Reagents. The soluble form of recombinant TRANCE/RANKL that we
used was described previously (16). Recombinant mouse M-CSF, IL-1 ,
and IL-1  were obtained from R & D Systems. A cell proliferation (WST-1)
kit was purchased from Roche Molecular Biochemicals. Unless otherwise
stated, all chemicals were from Sigma-Aldrich. A polyclonal antibody raised
in rabbits and directed against IRAK-M was purchased from Chemicon In-
ternational; rabbit polyclonal antibodies directed against p38, phosphory-
lated-p38, ERK1/2, P-ERK1/2, JNK, and mouse monoclonal antibodies
directed against P-I B and P-JNK were obtained from Cell Signaling. A
mouse monoclonal antibody directed against GAPDH was purchased from
Novus Biologicals, Inc. Horseradish peroxidase-conjugated F(ab )2 directed
against rabbit and mouse IgG was purchased from Jackson ImmunoRe-
search Laboratories. All supplies and reagents for tissue culture were endo-
toxin-free. Some bone marrow cells were treated with polymyxin B sulfate
for 24 h to avoid the effects of the endotoxin before treatment.
Bone marrow macrophages and osteoclasts. Bone marrow cells from
6- to 12-wk-old IRAK-M /  and IRAK-M /  male mice were plated in
10 cm dishes and cultured in  -MEM (Life Technologies) supplemented
with 10% FBS in the presence of M-CSF (5 ng/m; 107 cells/10-cm dish)
for 12–18 h. Nonadherent cells were harvested and cultured with M-CSF
(30 ng/ml) in 10 cm dishes, at the same density as before, for an additional
48 h. Floating cells were removed and attached cells, which are TRAP 
macrophages were used as osteoclast precursors (16).
To generate osteoclasts, we cultured bone marrow macrophages in the
presence of RANKL (300 ng/ml) and M-CSF (30 ng/ml) or a 30% (vol/
vol) dilution of the supernatant from a culture of L929 cells, in 96-well, 24-
well, or 60 mm dishes at a density of 0.5   106 cells/ml.
Cytokine arrays. Bone marrow macrophages from IRAK-M /  and
IRAK-M /  mice were plated, in duplicate wells, in 24-well dishes
(0.5   106 cells/well) and treated with 20 ng/ml M-CSF for 10–12 h.
Cells were starved for 4 h and then cultured unstimulated or stimulated for
24 h with 20 ng/ml M-CSF alone or in combination with 300 ng/ml
RANKL in 0.5 ml of serum-free medium. Supernatants were collected
and analyzed for cytokines using mouse cytokine antibody arrays (Raybio-
tech, Inc.). Signals on films were quantitated with National Institutes of
Health Image software.
Western blotting analysis. Cultured cells were lysed directly in Laem-
mli’s sample buffer supplemented with a cocktail of protease inhibitors
(Complete Tablets, Roche Molecular Biochemicals) and phosphatase inhib-
itors (sodium fluoride and sodium vanedate). The lysates were sonicated be-
fore analysis by electrophoresis and Western blotting with ECL  (Pierce
Chemical Co.).
Statistical analysis. Data in Tables I and II are means   1 SD. Statistically
significant differences among experimental groups were evaluated by the
analysis of variances (26). The significance of mean changes was determinedJEM VOL. 201, April 4, 2005 1177
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by an unpaired Student’s two-tailed t test, and significance was recognized
when P   0.05.
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